Blood-Based Biomarker Testing for Alzheimer Disease in US Clinical Practice
This cohort study examines the rates of blood-based biomarker testing for Alzheimer disease in US clinical practice, exploring patient characteristics, ordering clinician specialty, and diagnostic and treatment events.
Authors
- Reshma Ramachandran (ORCID: https://orcid.org/0000-0003-3845-3606)
- Joseph S. Ross (ORCID: https://orcid.org/0000-0002-9218-3320)
- Karina M. Berg (ORCID: https://orcid.org/0000-0001-7536-3760)
- Matthew Andersen (ORCID: https://orcid.org/0009-0003-7900-787X)
- Mengyuan Fu (ORCID: https://orcid.org/0000-0001-9703-8408)
Institutions
- University of Connecticut (US)
- Peking University (CN)
- Yale University (US)
- Yale New Haven Health System (US)
- UConn Health (US)
Publication Details
- Journal
- JAMA
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1001/jama.2026.23534
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00